A Study of LY3471851 in Participants With Psoriasis

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 26, 2019

Primary Completion Date

July 21, 2021

Study Completion Date

July 21, 2021

Conditions
Psoriasis
Interventions
DRUG

Placebo

Administered SC

DRUG

LY3471851

Administered SC

Trial Locations (24)

18249

DermDox Centers for Dermatology, Sugarloaf

19103

Paddington Testing Company Inc, Philadelphia

30328

Medical Dermatology Specialists, Sandy Springs

33134

Florida Academic Centers Research and Education, LLC, Coral Gables

33173

Miami Dermatology and Laser Research, Miami

40217

Skin Sciences, Louisville

40241

Forefront Research, Louisville

43215

Remington-Davis, Inc, Columbus

46250

Dawes Fretzin Clinical Research Group, LLC, Indianapolis

48047

Clinical Research Institute of Michigan, LLC, Chesterfield

48084

Derm Center, Troy

63117

Central Dermatology PC, St Louis

72117

Arkansas Research Trials, LLC, North Little Rock

73118

Unity Clinical Research, Oklahoma City

75034

Rodgers Dermatology, Frisco

77433

Studies in Dermatology, LLC, Cypress

77478

Complete Dermatology, Sugar Land

78229

Progressive Clinical Research, San Antonio

90404

Clinical Science Institute, Santa Monica

92024

California Dermatology & Clinical Research Institute, Encinitas

92123

Therapeutics Clinical Research, San Diego

94538

Center For Dermatology Clinical Research, Inc., Fremont

33613-1244

ForCare Clinical Research, Tampa

03801

ActivMed Practices and Research, Portsmouth

Sponsors
All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

Nektar Therapeutics

INDUSTRY

NCT04119557 - A Study of LY3471851 in Participants With Psoriasis | Biotech Hunter | Biotech Hunter